Buchang Pharma Subsidiaries Complete Drug Manufacturing License Updates

Corporate Action
โดย Jiemian·Read original
Summary · why it matters

Buchang Pharma announced that its wholly owned subsidiaries Buchang Gaoxin and Shaanxi Buchang Pharma completed changes to their Drug Manufacturing Licenses on July 24, 2026. Buchang Gaoxin added a contract manufacturing scope for capsules, added a pre-extraction workshop, a hard capsule production line in Solid Workshop II, and a tablet production line in Solid Workshop I, with its classification code changed to AhzChz. Shaanxi Buchang Pharma added production lines for Pramipexole Dihydrochloride Extended-Release Tablets and Suanzaoren Dihuang Capsules, removed the contract manufacturing scope for Kechuan'an Oral Liquid, and changed its classification code to AhzBhzCh.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 2

步长高新Private▲ Positive
Regulationrelevance

Buchang Gaoxin added contract manufacturing scope and new production lines, with license classification code changed.

陕西步长制药Private▲ Positive
Regulationrelevance

Shaanxi Buchang Pharma added production lines for specific drugs and removed contract manufacturing scope for another product.

© 2026 MarketDXNews